Eurofins-Cerep

M&A Activity • Oct 14, 2009

Cerep grants a BioPrint® evaluation licence to Roche

Paris, October 13, 2009 - press release 2009/09

Cerep [NYSE Euronext - CER] today announces the signature of a strategic collaboration with Roche on BioPrint®, the company's homogenous pharmacology and ADME database, which provides a unique resource for supporting decision making in drug discovery. The BioPrint® database is composed of three main data sets: chemical descriptors (structures and chemical information, 2D and 3D descriptors), in vitro profiles and in vivo effects of tested compound.

Under the terms of the agreement, Roche will be granted access to the BioPrint® database and related pharmaco-informatics tools. In addition, Cerep will generate new BioPrint® data on Roche compounds for Roche's exclusive use.

Roche and Cerep will also collaborate on further development of BioPrint® and related pharmaco-informatics tools aimed at predicting as early as possible adverse drug reactions which could lead to failure during clinical trials.

An initial licence is granted for a maximum term of two years to evaluate the integration of BioPrint® within Roche research strategy. During this evaluation phase, a limited number of users will be given a web access to BioPrint® data and tools. At the end of this period, Roche will have the option to subscribe a perpetual licence at a pre determined price.

Cerep will receive an annual license fee and payments for the generation of new BioPrint® data.

"We are very happy to announce a new collaboration on BioPrint®. This agreement with Roche will certainly allow us to further enhance and accelerate the development and validation of predictive tools, especially in the field of adverse clinical effects of drug-candidates" commented Thierry Jean, President & CEO of Cerep.

About BioPrint®

Based on a unique database and on proprietary informatics tools, BioPrint® places a new drug candidate in the context of marketed drugs, anticipating potential in vivo liabilities, predicting off-target activities, and ADME characteristics (Drug profile interpretation).

In another application, BioPrint® serves to identify secondary targets that are not genetically parented to a test target (Target profile design).

Contacts

Thierry Jean, Chairman & CEO Sophie Macault, General Counsel & Corporate Secretary Tel. +33 (0)1 45 64 44 60 fincom@cerep.fr

Code ISIN FR0004042232 Euronext Paris Euronext - Local Securities

Cerep SA 155 boulevard Haussmann 75008 Paris France tel + 33(0)145 64 44 60 fax +33(0)145 64 44 64 e-mail: fincom@cerep.fr www.cerep.com

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forwardlooking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.